Merck’S Remigromig, A Tri-Specific Agonist Of The Wingless-Related Integration Site Pathway, Met Primary Endpoint In The Pivotal Phase 2B/3 Brunello Study Of Adults With Diabetic Macular Edema
Merck & Co Inc NYSE:MRK
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
4 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
BRIEF — Merck’S Remigromig, A Tri — Specific Agonist Of The Wingless — Related Integration Site Pathway, Met Primary Endpoint In The Pivotal Phase 2B/3 Brunello Study Of Adults With Diabetic Macular Edema
Sept 24 (Reuters) — Merck & Co Inc: Merck’s Remigromig, A Tri-specific Agonist Of The Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint In The Pivotal Phase 2b/3 Brunello Study Of Adults With Diabetic Macular Edema Merck & Co - Remigromig Demonstrates Non-inferiority To Ranibizumab For Bcva At Week
Merck’s Remigromig, a Tri — specific Agonist of the Wingless — related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
For best results when printing this announcement, please click on link below: Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema Remigromig demonstrated non-inferiority to
Merck’s Remigromig, a Tri-specific Agonist of the Wingless-related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2b/3 BRUNELLO Study of Adults with Diabetic Macular Edema
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced topline results from the pivotal Phase 2b/3 BRUNELLO trial in adults with diabetic macular edema (DME). BRUNELLO is the first of two Phase 2b/3 trials evaluating the safety and efficacy of remigromig (MK-3000…